Portal de Periódicos da CAPES

Human Immunodeficiency Virus Type 1 RNA Level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-Analysis

2000; Mary Ann Liebert, Inc.; Volume: 16; Issue: 12 Linguagem: Inglês

10.1089/088922200414965

1931-8405

Abdel Babiker, J. Bartlett, AM Breckenridge, Gary Collins, Robert W. Coombs, David A. Cooper, Tracy Creagh, Anne Cross, Michael J. Daniels, J. Darbyshire, Dana Dawson, Victor DeGruttola, Ralph DeMasi, Raphael Dolin, Joseph J. Eron, Margaret A. Fischl, Sidney E. Grossberg, John D. Hamilton, Hammer Sm, Pamela Hartigan, Keith Henry, Andrew Hill, Michael D. Hughes, James S. Kahn, Christine Katlama, David Katzenstein, Sung Woo Kim, Donna Mildvan, Joan Montaner, M. Moore, J. Neaton, Wendy O’Brien, Heather J. Ribaudo, D. D. Richman, Michael S. Saag, Miklos Salgo, Louis D. Saravolatz, Robert T. Schooley, M Séligmann, Schlomo Staszewski, Lesley Struthers, C. Tierney, Anastasios A. Tsiatis, Seth L. Welles, Michael D. Hughes,

HIV/AIDS Research and Interventions

AIDS Research and Human RetrovirusesVol. 16, No. 12 ArticlesHuman Immunodeficiency Virus Type 1 RNA Level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-AnalysisPublished Online:5 Jul 2004https://doi.org/10.1089/088922200414965AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail AbstractObjective: To evaluate treatment-mediated changes in HIV-1 RNA and CD4 count as prognostic markers and surrogate end points for disease progression (AIDS/death). Methods: Data from 13,045 subjects in all 16 randomized trials comparing nucleoside analogue reverse transcriptase inhibitors and having HIV-1 RNA measurements at 24 weeks were obtained. A total of 3146 subjects had HIV-1 RNA and CD4 count determinations at 24 weeks after starting treatment. Results: At Week 24, the percentage of subjects experiencing an HIV-1 RNA decrease of >1 log10 copies/ml or a CD4 count increase of >33% was similar (22% vs 25%). Changes in both markers at Week 24 were significant independent predictors of AIDS/death: across trials, the average reduction in hazard was 51% per 1 log10 HIV-1 RNA copies/ml decrease (95% confidence interval: 41%, 59%) and 20% per 33% CD4 count increase (17%, 24%). In univariate analyses, the hazard ratio for AIDS/death in randomized treatment comparisons was significantly associated with differences between treatments in mean area under the curve of HIV-1 RNA changes to Weeks 8 and 24 (AUCMB) and mean CD4 change at Week 24, but, in multivariate analysis, only mean CD4 change was significant. Conclusions: Change in HIV-1 RNA, particularly using AUCMB, and in CD4 count should be measured to aid patient management and evaluation of treatment activity in clinical trials. However, short-term changes in these markers are imperfect as surrogate end points for long-term clinical outcome because two randomized treatment comparisons may show similar differences between treatments in marker changes but not similar differences in progression to AIDS/death. FiguresReferencesRelatedDetailsCited byThe performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis22 August 2022 | PLOS Medicine, Vol. 19, No. 8Outcomes of Cervical Cancer in HIV-Positive Women Treated With Radiotherapy at a Tertiary Care Center in IndiaJCO Global Oncology, No. 8Performance Evaluation of BD FACSPrestoTM Near-Patient CD4 Counter for Monitoring Antiretroviral Therapy in HIV-Infected Individuals in Primary Healthcare Clinics in Thailand2 February 2022 | Diagnostics, Vol. 12, No. 2Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection13 February 2020 | Clinical Infectious Diseases, Vol. 72, No. 5HIV viral exposure and mortality in a multicenter ambulatory HIV adult cohort, United States, 1995–201625 June 2021 | Medicine, Vol. 100, No. 25Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans1 January 2021 | Infection & Chemotherapy, Vol. 53Viral load outcomes in a cohort of alcohol-consuming people living with HIV receiving antiretroviral therapy in Mumbai, India11 June 2020 | International Journal of STD & AIDS, Vol. 31, No. 8Predictors of postpartum HIV care engagement for women enrolled in prevention of mother-to-child transmission (PMTCT) programs in Tanzania22 November 2018 | AIDS Care, Vol. 31, No. 6Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen1 May 2019 | International Journal of STD & AIDS, Vol. 30, No. 7Associations between drug use patterns and viral load suppression among HIV-positive individuals who use support services in New York CityDrug and Alcohol Dependence, Vol. 197Factors Associated with Postpartum Loss to Follow-Up and Detectable Viremia After Delivery Among Pregnant Women Living with HIV Emily H. Adhikari, Casey S. Yule, Scott W. Roberts, Vanessa L. Rogers, Jeanne S. Sheffield, Mary Ann Kelly, Donald D. McIntire, and Arti Barnes2 January 2019 | AIDS Patient Care and STDs, Vol. 33, No. 1Validation of CD4+ T-cell and viral load data from the HIV-Brazil Cohort Study using secondary system data4 December 2018 | BMC Infectious Diseases, Vol. 18, No. 1Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individualsAIDS, Vol. 32, No. 17Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?6 February 2017 | BMC Infectious Diseases, Vol. 17, No. 1High HPgV replication is associated with improved surrogate markers of HIV progression14 September 2017 | PLOS ONE, Vol. 12, No. 9Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected PatientsJournal of Clinical Microbiology, Vol. 55, No. 8An integrative review of the efficacy of motivational interviewing in HIV managementPatient Education and Counseling, Vol. 100, No. 4Assessment of the antiviral capacity of primary natural killer cells by optimized in vitro quantification of HIV-1 replicationJournal of Immunological Methods, Vol. 434Human Immunodeficiency Virus7 March 2016The Association Between Food Insufficiency and HIV Treatment Outcomes in a Longitudinal Analysis of HIV-Infected Individuals in New York CityJAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 69, No. 3Crystal methamphetamine use and HIV medical outcomes among HIV-infected men who have sex with men accessing support services in New YorkDrug and Alcohol Dependence, Vol. 147EFFECT OF ANTI-RETROVIRAL THERAPY ON CD4+ T LYMPHOCYTE COUNT IN HIV INFECTED PATIENTS ATTENDING REGIONAL INSTITUTE OF MEDICAL SCIENCES HOSPITAL, MANIPUR19 November 2013 | Journal of Evolution of Medical and Dental sciences, Vol. 2, No. 47Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial14 November 2013 | PLoS ONE, Vol. 8, No. 11Dynamical models of biomarkers and clinical progression for personalized medicine: The HIV contextAdvanced Drug Delivery Reviews, Vol. 65, No. 7Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: Results of analyses from a multicenter randomized trial30 October 2012 | BMC Infectious Diseases, Vol. 12, No. 1Physiological and Laboratory Markers of Drug EffectCumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS20 May 2011 | PLoS ONE, Vol. 6, No. 5Clinical Outcome of HIV-Infected Patients with Discordant Virological and Immunological Response to Antiretroviral Therapy1 February 2011 | The Journal of Infectious Diseases, Vol. 203, No. 3Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010Current Opinion in HIV and AIDS, Vol. 5, No. 6CD4 T Cell Assessments in Evaluation of HIV Therapeutics27 October 2010Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell countsHIV Medicine, Vol. 11, No. 5Towards a combined prognostic index for survival in HIV infection: the role of ânon-HIVâ biomarkersHIV Medicine, Vol. 11, No. 2Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field15 February 2010 | Clinical Trials, Vol. 7, No. 1Wertigkeit des Biomarkers BNP bei HIV-infizierten Patienten13 January 2010 | Herz, Vol. 34, No. 8Meta-analytical Studies on the Epidemiology, Prevention, and Treatment of Human Immunodeficiency Virus InfectionInfectious Disease Clinics of North America, Vol. 23, No. 2Human Immunodeficiency Virus27 February 2009CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected Individuals8 September 2008 | PLoS ONE, Vol. 3, No. 9Evaluation of change in CD4+ cell counts in AIDS clinical trials14 August 2007 | Statistical Methods in Medical Research, Vol. 17, No. 2Clinical outcomes in clinical trials of anti-HIV treatmentFuture HIV Therapy, Vol. 1, No. 3Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 TrialClinical Infectious Diseases, Vol. 43, No. 10Reporting and Evaluation of HIV-Related Clinical Endpoints in Two Multicenter International Clinical Trials2 February 2015 | HIV Clinical Trials, Vol. 7, No. 3The CD4 lymphocyte count and risk of clinical progressionCurrent Opinion in HIV and AIDS, Vol. 1, No. 1Counterfactual Links to the Proportion of Treatment Effect Explained by a Surrogate Marker23 June 2005 | Biometrics, Vol. 61, No. 4Predictors of death within six months in patients with advanced AIDS13 April 2006 | Palliative and Supportive Care, Vol. 3, No. 4Key Issues in End Point Selection for Heart Failure Trials: Composite End PointsJournal of Cardiac Failure, Vol. 11, No. 8Nutrition Society Symposium on 'End points in clinical nutrition trials' Death, morbidity and economics are the only end points for trials7 March 2007 | Proceedings of the Nutrition Society, Vol. 64, No. 03Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort studyThe Lancet, Vol. 366, No. 9483Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 39, No. 3Comparison of Prognostic Importance of Latest CD4+ Cell Count and HIV RNA Levels in Patients with Advanced HIV Infection on Highly Active Antiretroviral Therapy2 February 2015 | HIV Clinical Trials, Vol. 6, No. 3Reliability of CD4 Quantitation in Human Immunodeficiency Virus-Positive Children: Implications for Definition of Immunologic Response to Highly Active Antiretroviral TherapyClinical Diagnostic Laboratory Immunology, Vol. 12, No. 5Serum Neopterin, an Immune Activation Marker, Independently Predicts Disease Progression in Advanced HIV-1 InfectionClinical Infectious Diseases, Vol. 40, No. 6Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIVJournal of Clinical Virology, Vol. 31A Randomized Trial of Multivitamin Supplements and HIV Disease Progression and MortalityNew England Journal of Medicine, Vol. 351, No. 1Early Markers of HIV-1 Disease Progression in a Prospective Cohort of Seroconverters in Bangkok, ThailandJAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 36, No. 3Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infectionAIDS, Vol. 18, No. 3A Randomized Clinical Trial Comparing Nelfinavir and Ritonavir in Patients with Advanced HIV Disease (CPCRA 042/CTN 102)2 February 2015 | HIV Clinical Trials, Vol. 5, No. 1Lymphocyte Counts Independently Predict Overall Survival in Advanced Cancer Patients: A Biomarker for IL-2 ImmunotherapyJournal of Immunotherapy, Vol. 26, No. 5Clinical Progression in Early and Late Stages of Disease in a Cohort of Individuals Infected with Human Immunodeficiency Virus-2 in Guinea-Bissau8 July 2009 | Scandinavian Journal of Infectious Diseases, Vol. 35, No. 4Evaluating surrogate endpointsControlled Clinical Trials, Vol. 23, No. 6The role of MRI as a surrogate outcome measure in multiple sclerosis13 November 2017 | Multiple Sclerosis Journal, Vol. 8, No. 1_supplPrognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesThe Lancet, Vol. 360, No. 9327Viral Load as a Surrogate End Point in HIV Disease26 June 2016 | Annals of Pharmacotherapy, Vol. 36, No. 2The role of MRI as a surrogate outcome measure in multiple sclerosis2 July 2016 | Multiple Sclerosis Journal, Vol. 8, No. 1Imaging and neurochemical markers for diagnosis and disease progression in ALSJournal of the Neurological Sciences, Vol. 191, No. 1-2An Open-Label Randomized Trial to Evaluate Different Therapeutic Strategies of Combination Therapy in HIV-1 InfectionControlled Clinical Trials, Vol. 22, No. 2Can a Marker Be a Surrogate for Development of Cancer, and Would We Know It if It Exists?HIV-1 Vaccine Testing, Trial Design, and Ethics Volume 16Issue 12Aug 2000 To cite this article:Human Immunodeficiency Virus Type 1 RNA Level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-Analysis.AIDS Research and Human Retroviruses.Aug 2000.1123-1133.http://doi.org/10.1089/088922200414965Published in Volume: 16 Issue 12: July 5, 2004PDF download